Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches
Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches
Crossover study of DFN-15 dose A versus DFN-15 dose B versus Placebo in the treatment of
 migraine headaches.
Inclusion Criteria:

 1. Patients with a history of episodic migraine (as defined by International
 Classification of Headache Disorders [ICHD]-228) who experience an average of 2 to 6
 migraine attacks a month for the past 12 months with no more than 14 headache days per
 month, and with at least 48 hours of headache-free time between migraine attacks;

 2. Patients with onset of migraine with or without aura before age 50;

 3. Patients who have migraine with or without aura, in which the aura cannot last longer
 than 60 minutes;

 4. Patients who report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain
 severity scale.

 Exclusion Criteria:

 1. Patients with medication overuse headache (MOH) as defined by ICHD-228:

 -  Opioids ≥ 10 days a month during the 90 days prior to screening

 -  Combination medications (eg, Fiorinal® ≥ 10 days a month)

 -  Nonsteroidal anti-inflammatory drugs (NSAIDs) or other simple medications > 14
 days a month during the 90 days prior to screening

 -  Triptans or ergots ≥ 10 days a month during the 90 days prior to screening

 2. Patients on chronic warfarin sodium;

 3. Patients taking monoamine oxidase-A (MAO-A) inhibitors;

 4. Patients on unstable dosages of chronic medications during the 3 months prior to and
 through screening, or who are not willing or able to maintain a stable pre-study dose
 throughout study participation;

 5. Patients with more than 6 migraine attacks a month and/or more than 14 headache days a
 month (based upon patient self-report);

 6. Patients with hemiplegic migraine or migraine with brain stem aura or other forms of
 neurologically complicated migraine;

 7. Patients with atypical aura;

 8. Patients with prolonged aura (more than 1 hour).

 9. Patients with a history of stroke or transient ischemic attack;

 10. Patients with a history of migralepsy or a concurrent diagnosis of seizure disorder;

 11. Patients who cannot differentiate between a migraine headache and a tension-type or
 cluster headache or any other non-migraine headache;

 12. Patients with a history of more than 10 tension-type headaches per month;

 13. Patients with a history of cluster headache;

 14. Patients with a diagnosis of ICHD-2 "probable migraine";

 15. Patients with uncontrolled hypertension (screening blood pressure ≥ 140/90 mmHg
 despite appropriate pharmacotherapy);

 16. Patients with severe renal impairment (defined as serum creatinine > 1.9 mg/dL);

 17. Patients with serum total bilirubin > 1.9 mg/dL;

 18. Patients with serum aspartate aminotransferase (AST), alanine aminotransferase (ALT),
 or alkaline phosphatase > 3 times the upper limit of normal;

 19. Patients with positive serology for human immunodeficiency virus (HIV), Hepatitis B
 surface antigen, Hepatitis C antibody.

 20. Patients with a history of alcohol or substance abuse (including marijuana and medical
 marijuana) within 1 year that would compromise data collection;

 21. Patients with a history of or current neurological or psychiatric impairment, or
 cognitive dysfunction that, in the opinion of the investigator, would compromise data
 collection;

 22. Patients with any other medical condition that, in the judgment of the investigator or
 medical monitor, would confound the objectives of the study (eg, cancer history
 [except basal cell carcinoma], systemic lupus erythematosus);

 23. Patients who have participated in a clinical trial involving any medication during the
 past 30 days or 5 half-lives of the study medication, whichever is longer